Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. has called a special stockholder meeting to approve several corporate actions. The main item seeks approval, for Nasdaq Listing Rule 5635(d) purposes, to allow the exercise of warrants for up to 64,864,864 shares of common stock issued in an August 28, 2025 private placement. These Series F warrants carry a $0.55 exercise price, a five‑year term from stockholder approval, anti‑dilution adjustments with a floor price of $0.11, and beneficial ownership limits of 4.99% or 9.99% at each holder’s election.
If fully exercised for cash at the initial exercise price, the company states it would receive approximately $35.7 million in proceeds, compared with 36,739,360 shares of common stock outstanding as of August 28, 2025. Stockholders are also being asked to approve changing the corporate name to Moleculin Inc. and to authorize potential adjournment of the meeting to solicit additional proxies if needed. The Board unanimously recommends voting in favor of all three proposals.
Moleculin Biotech, Inc. reported two corporate actions in this Current Report. Stockholders approved and the company filed a Certificate Amendment to increase authorized common shares from 100,000,000 to 500,000,000, which became effective upon filing with the Delaware Secretary of State on August 21, 2025. The company also furnished a press release dated August 27, 2025 announcing completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin combined with Cytarabine (referred to as AnnAraC) for treatment of subjects with acute myeloid leukemia (AML). The Certificate Amendment and the press release are attached as exhibits.
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K reporting a Regulation FD disclosure that the company posted an investor presentation dated August 2025 to its website and furnished the presentation as Exhibit 99.1. The filing clarifies the furnished exhibit is not being "filed" under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless expressly stated. No financial results, transactions, or forward-looking guidance are included in this report.
Moleculin Biotech, Inc. reported results from its annual meeting held August 18, 2025. Stockholders elected six directors to serve until the next annual meeting and approved several governance and compensation measures. Shareholders approved an amendment to the 2024 Equity Incentive Plan, a non-binding advisory vote on executive compensation, the issuance of up to 6,542,058 shares upon exercise of certain warrants issued February 26, 2025, an amendment increasing authorized common shares from 100,000,000 to 500,000,000, and an amendment granting the board authority to effect a reverse stock split. The proposal to eliminate supermajority voting requirements was not approved.
Vote totals are reported for each matter (for example, Proposal to increase authorized shares: 4,320,277 for, 1,697,864 against, 22,971 abstentions). The report was signed by the Chief Financial Officer.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,586,521 shares of Moleculin Biotech, Inc. common stock, representing 4.99% of the class. The filing states that Armistice Capital, as investment manager of its Master Fund, and Mr. Boyd as its managing member, exercise shared voting and dispositive power over these shares; neither reports sole voting or dispositive power. The Master Fund is identified as the direct holder while disclaiming direct beneficial ownership due to the investment management agreement. The statement affirms the holdings were acquired in the ordinary course of business.
Moleculin Biotech, Inc. disclosed that it issued a press release reporting its financial results for the quarter ended June 30, 2025 and recent operational highlights. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.
The 8-K filing itself does not present numerical revenue, profit, cash flow or balance sheet figures; investors must consult the attached press release for detailed results and metrics. The company’s common stock trades under the ticker MBRX on The NASDAQ Stock Market. The filing also lists an Inline XBRL cover page as Exhibit 104, indicating machine-readable cover data is included with the submission.
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company advancing its lead drug Annamycin in a global Phase 3 pivotal trial (MIRACLE). As of June 30, 2025, the company reported $7.6 million in cash, $21.6 million in total assets, $28.8 million in total liabilities and an accumulated deficit of $167.4 million. Net loss was $7.64 million for Q2 2025 and $14.08 million for the six months ended June 30, 2025. The company recorded a $20.55 million warrant liability and recognized a $10.4 million loss on issuance related to its June 2025 offering.
The MIRACLE Phase 3 program is active in 35+ sites across the US, EU and Eastern Europe with 8 subjects treated as of July 25, 2025 and planned interim unblinding by end of 2025. Regulators: EMA approved CTAs for nine EU countries; FDA provided positive pediatric study feedback. Nasdaq notified the company of deficiencies on equity and bid-price listing standards; a plan to regain compliance was submitted on July 3, 2025. Management disclosed substantial doubt about going concern and is seeking additional financing.
Item 7.01 – Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application “Preparation of Pre-liposomal Annamycin Lyophilizate.”
The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company’s Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.